NASDAQ$TELA
TELA Bio Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
TELA Bio reported a net loss of $8.6 million in Q3 2025 despite revenue growth driven by international expansion and product launches.
TELA Bio saw a 9% revenue increase in Q3 2025, supported by international sales and new product configurations. While gross profit improved, the company continued to operate at a loss. Operating expenses decreased year-over-year, and the company ended the quarter with nearly $30 million in cash.
- Revenue rose to $20.7 million, up 9% year-over-year.
- Gross profit reached $14.0 million, with a 67.5% gross margin.
- Net loss was $8.6 million, showing an improvement over the $10.4 million loss last year.
- Cash and cash equivalents totaled $29.7 million at the end of the quarter.
Headline financials
Revenue & EPS history
TELA Bio · Revenue · Quarterly
$20.7M
Forward guidance
TELA Bio expects full-year 2025 revenue growth of at least 16%, supported by product portfolio enhancements and sales expansion.
Tailwinds
- Revenue guidance raised to at least 16% growth for FY2025
- Credit facility up to $70 million secured to strengthen liquidity
- Completed hiring goals for U.S. sales force expansion
- Continued international growth momentum
- New product configurations positively impacted sales
Headwinds
- Net loss continued in Q3 2025 despite improved operating performance
- Gross margin slightly decreased from the prior year
- Revenue growth partially offset by pricing pressure due to product mix
- Total assets declined significantly year-over-year
- No specific breakdown of revenue contribution from new segments or regions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
-2.5%
Avg return
Earnings day
-3.7%
Avg return
5 days after
+3.7%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+20.2%
Q1 2024
Best reaction
-37.2%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -18.6% | — | |
| Q4 2025 | +1.7% | -25.8% | -12.0% | |
| Q3 2025 | -9.3% | -2.7% | +3.6% | |
| Q1 2025 | +7.2% | -0.1% | +90.7% | |
| Q4 2024 | -37.2% | -44.9% | -59.1% | |
| Q3 2024 | +2.0% | +3.0% | -1.7% | |
| Q2 2024 | -23.9% | -23.4% | -35.0% | |
| Q1 2024 | +20.2% | +21.2% | +16.7% | |
| Q4 2023 | +4.0% | +0.9% | -13.8% | |
| Q3 2023 | -20.3% | -21.7% | -4.5% | |
| Q2 2023 | -4.8% | -1.2% | -2.8% | |
| Q1 2023 | -3.6% | -4.8% | +11.2% | |
| Q4 2022 | -5.5% | -3.7% | -11.3% | |
| Q3 2022 | +13.8% | +11.2% | +44.7% | |
| Q2 2022 | -6.5% | +5.5% | +0.9% | |
| Q1 2022 | -5.7% | -7.0% | -31.4% | |
| Q4 2021 | -4.8% | -4.8% | -20.4% | |
| Q3 2021 | -3.8% | -3.7% | -1.7% | |
| Q2 2021 | +5.0% | +4.4% | -8.3% | |
| Q1 2021 | +3.2% | +11.5% | +5.9% | |
| Q4 2020 | -6.6% | +0.9% | -1.8% | |
| Q3 2020 | -3.5% | -0.8% | -3.6% | |
| Q2 2020 | +5.4% | +4.1% | +20.7% | |
| Q1 2020 | -2.4% | -3.6% | +38.6% | |
| Q4 2019 | +0.6% | -0.4% | +34.0% | |
| Q3 2019 | +13.9% | +8.8% | +32.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro